ai3Bio emerged from stealth with $48 million in funding as it targets autoimmune disease by eliminating specific T helper cell subsets rather than broadly depleting B cells. The company positions its immune-reset approach as “taking the gun out of the hands of the immune system,” pointing to a more selective mechanism intended to reduce collateral effects. The funding signals investor appetite for mechanism-driven autoimmune strategies, especially those that seek to improve safety and efficacy versus earlier immune depletion approaches. The company’s platform focus aligns with the broader industry movement toward cell-type selective immunomodulation. While early-stage details weren’t fully laid out, the emergence adds another competitor to the increasingly crowded autoimmune landscape that spans bispecifics, engineered T-cell therapies and novel immune reset modalities. For biotech professionals, ai3Bio’s launch is a reminder that the next wave of autoimmune investment is increasingly centered on precise cell-state targeting rather than single-target blockade.